Human Trials

ViiV Healthcare begins third phase III HIV trial of cabotegravir/rilpivirine regimen

ViiV Healthcare, a joint venture of GSK, Pfizer and Shionogi, has commenced a phase III study with a two-drug regimen of its long-acting, injectable cabotegravir and Janssen Sciences Ireland’s long-acting injectable rilpivirine in virally suppressed adults with HIV-1 infection.

Cancer Research UK to use Astra Zeneca’s AZD1775 in head and neck cancer trial

UK researchers are all set to launch an early-stage trial to evaluate an experimental drug from Astra Zeneca’s for improving the treatment of head and neck cancer.

Cytokinetics’ ALS treatment tirasemtiv fails to meet primary endpoint in phase 3 study

Cytokinetics has announced that international phase 3 clinical trial of tirasemtiv in patients with amyotrophic lateral sclerosis (ALS) has did not meet the primary endpoint.

Summit completes initial dosing trials on Duchenne muscular dystrophy drug

Summit Therapeutics has completed the half-way stage of dosing of its Duchenne Muscular Dystrophy (DMD) candidate ezutromid in a 48-week phase 2 trial, dubbed PhaseOut DMD.

Sage’s brexanolone meets primary endpoints in phase 3 postpartum depression trials

Sage Therapeutics has reported positive top-line results from two phase 3 clinical trials with its i.v. formulation of brexanolone (USAN; formerly SAGE-547); Study 202B in severe postpartum depression (PPD) and Study 202C in moderate PPD.

Tricida announces closing of $57.5m series D financing

Tricida has closed an oversubscribed $57.5m series D financing, bringing the company’s total capital raised to-date to $153.3m.

Boehringer says Cyltezo and Humira have similar efficacy, safety in people with RA

Boehringer Ingelheim has revealed one-year data from VOLTAIRE-RA, a pivotal phase 3 clinical trial evaluating Cyltezo (adalimumab-adbm) with reference product Humira.

Trial finds blood plasma infusions could help treat Alzheimer’s

A team of researchers in the US have found that regular infusions of blood plasma from young donors could well be a new treatment option for Alzheimer’s disease.

Sanofi, Alnylam present positive complete results of patisiran from phase 3 study in hATTR amyloidosis patients with polyneuropathy

Sanofi Genzyme, and Alnylam Pharmaceuticals have reported positive complete results from the Apollo Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy.